US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

22.05

+0.65003.04%

Volume:306.60K

Turnover:6.66M

Market Cap:3.88B

PE:-17.67

High:22.22

Open:21.44

Low:21.43

Close:21.40

Loading ...

Overview Company News Filings

Onestream Inc Outlook FY25 Adj EPS $0.01 - $0.09

THOMSON REUTERS

Press Release: OneStream Announces Fourth Quarter and Fiscal Year 2024 Financial Results

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

CVM: Fiscal Year 2024 Results

Zacks Small Cap Research

Onestream, Inc. (OS) Among the Best Software Infrastructure Stocks to Buy According to Analysts

OneStream Inc expected to post earnings of 2 cents a share - Earnings Preview

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

KKR quarterly profit beats expectation on dealmaking revival

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

Pfizer's Groundbreaking Cancer Drug Hits a Major Milestone--What It Means for Investors

Why Netflix's Excellent Performance Is a Great Reason to Buy Roku Stock

Immutep Quarterly Activities Report Q2 FY25

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25…

Zacks Small Cap Research

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OS/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":22.05,"timestamp":1746114158361,"preClose":21.4,"halted":0,"volume":306600,"delay":0,"floatShares":70199725,"shares":176023203,"eps":-1.247698,"marketStatus":"Trading","change":0.65,"latestTime":"05-01 11:43:24 EDT","open":21.44,"high":22.22,"low":21.43,"amount":6660582.6924,"amplitude":0.036916,"askPrice":22.08,"askSize":20,"bidPrice":22.02,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.247698,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746129600000},"marketStatusCode":2,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":21.4,"preHourTrading":{"tag":"盘前","latestPrice":21.68,"preClose":21.4,"latestTime":"09:29 EDT","volume":3962,"amount":85892.85173000001,"timestamp":1746106199999},"postHourTrading":{"tag":"盘后","latestPrice":21.4,"preClose":21.4,"latestTime":"16:12 EDT","volume":22219,"amount":475472.48,"timestamp":1746043930471},"volumeRatio":1.214582,"impliedVol":0.7785,"impliedVolPercentile":0.9053},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":70199725,"roa":"-33.71%","roe":"-102.65%","lyrEps":-1.232998,"volumeRatio":1.214582,"shares":176023203,"dividePrice":0,"high":22.22,"amplitude":0.036916,"preClose":21.4,"low":21.43,"week52Low":16.6942,"pbRate":"10.05","psRate":"7.93","week52High":35.39,"institutionHeld":0,"latestPrice":22.05,"committee":0.666667,"eps":-1.247698,"divideRate":0,"volume":306600,"delay":0,"ttmEps":-1.247698,"open":21.44,"prevYearClose":28.52,"prevWeekClose":21.29,"prevMonthClose":21.4,"prevQuarterClose":21.34,"fiveDayClose":21.27,"twentyDayClose":22.48,"sixtyDayClose":29.76,"earningDate":1746633600000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510357523","title":"Onestream Inc Outlook  FY25 Adj EPS $0.01 - $0.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2510357523","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510357523?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:11","pubTimestamp":1739308285,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P21LD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2510352091","title":"Press Release: OneStream Announces Fourth Quarter and Fiscal Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2510352091","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510352091?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:05","pubTimestamp":1739307900,"startTime":"0","endTime":"0","summary":"BIRMINGHAM, Mich., Feb. 11, 2025 /PRNewswire/ -- OneStream, Inc. , the leading enterprise Finance management platform that modernizes the Office of the CFO by unifying core finance and operational functions -- including financial close, consolidation, reporting, planning and forecasting -- today announced financial results for its fourth quarter and fiscal year ended December 31, 2024.-- Total Revenue: $132.5 million, an increase of 29% year-over-year.-- Subscription Revenue: $118.6 million, an increase of 35% year-over-year.-- GAAP Operating Income / Loss and Operating Margin: GAAP operating loss. was $47.4 million compared to income of $0.2 million for the fourth. quarter of 2023, and GAAP operating margin was (36%) compared to 0% for. the fourth quarter of 2023. This included equity-based compensation. expense of $52.6 million, compared to $1.2 million for the fourth quarter. -- Non-GAAP Operating Income and Non-GAAP Operating Margin: Non-GAAP. operating income was $8.7 million comp","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","TM","IE0004086264.USD","LU0672654240.SGD","LU2430703251.USD","BK4504","LU1868837136.USD","IE00BBT3K403.USD","SG9999004303.SGD","IE00B3S45H60.SGD","LU0894485498.HKD","LU2097344357.USD","LU2506951875.HKD","SG9999014906.USD","LU1116320901.HKD","LU2264538146.SGD","LU0689626769.HKD","LU2028103732.USD","IE00BQXX3D17.EUR","MSFT","03160","LU1803068979.SGD","LU1629891620.HKD","LU2298321311.HKD","R","LU0029864427.USD","IE00B1XK9C88.USD","LU2430703095.HKD","LU2286300806.USD","BK4533","LU0072461881.USD","SG9999014880.SGD","SG9999014542.SGD","LU1035775433.USD","LU0256863902.USD","OS","LU1989772923.USD","LU2108987350.USD","LU1861127337.USD","SG9999018865.SGD","LU1778281490.HKD","LU0265550946.USD","LU0162691827.USD","LU0823434740.USD","BK4232","LU1691799644.USD","LU0096364046.USD","LU0757359954.USD","LU0187121727.USD","LU0472753341.HKD"],"gpt_icon":1},{"id":"2510356549","title":"Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo","url":"https://stock-news.laohu8.com/highlight/detail?id=2510356549","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510356549?lang=en_us&edition=fundamental","pubTime":"2025-02-12 03:13","pubTimestamp":1739301234,"startTime":"0","endTime":"0","summary":"On Monday, Pfizer Inc. and Astellas Pharma Inc.   released additional follow-up results from the Phase 3 EV-302 trial  of Padcev plus Keytruda  in patients with previously untreated locally advanced or metastatic urothelial cancer .Also Read: Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook. The results showed a sustained overall survival  and progression-free survival  benefit consistent with the findings of the primary analysis after an additional 12 months of follow-up .Results showed enfortumab vedotin plus pembrolizumab reduced the risk of death by 49% versus chemotherapy.The median OS was 33.8 months for the combination versus 15.9 months for chemotherapy.The OS benefit was observed in all prespecified subgroups, including cisplatin eligible and ineligible subgroups.The median PFS was 12.5 months for the combination versus 6.3 months for chemotherapy.In addition to longer follow-up data, an exploratory analysis evalu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-astellas-tout-encouraging-data-191354087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999002232.USD","MRK","ALPMY","LU0321505868.SGD","ALPMF","BK4585","BK4534","LU1057294990.SGD","SG9999002224.SGD","BK4007","LU0058720904.USD","BK4581","LU0868494617.USD","BK4211","LU0306807586.USD","SG9999011175.SGD","BK4568","LU1066051498.USD","LU0456855351.SGD","BK4533","SG9999003800.SGD","LU0321505439.SGD","BK4599","LU0122379950.USD","LU1894683348.USD","LU0225771236.USD","BK4550","LU0306806265.USD","BK4592","SG9999013999.USD","IE00BBT3K403.USD","LU0289739699.SGD","LU1894683264.USD","LU0170899867.USD","BK4195","PFS","LU1066053197.SGD","LU0985481810.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","BK4097","IE0002270589.USD","LU1883839398.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU0225284248.USD","PFE","BK4588","OS","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2510332348","title":"Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332348","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510332348?lang=en_us&edition=fundamental","pubTime":"2025-02-12 00:55","pubTimestamp":1739292914,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now.In this article, we are going to take a look at where Immutep Limited  stands against the other long term ASX stocks.Vanguard believes that Australia's economy remains well-placed to recover gradually in 2025 after the broader economy witnessed its slowest growth in 32 years in 2024 amid sticky inflation and higher interest rates. The investment firm expects modest improvement in economic momentum, courtesy of higher real household incomes as inflation subsides. Furthermore, a rebounding housing market and expectations of rate cuts might also provide some support.Key Indicators Likely to Shape Australia's Economy in 2025. The Reserve Bank of Australia  kept the policy rate target unchanged at 4.35% on December 10. However, the bank noted that it continues to see signs of inflation moving sustainably towards the target. That being said, Vanguard expects that RBA will remain patient and that a tight labor market i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-limited-immp-best-long-165514394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2098885051.SGD","LU1815336091.USD","IMM.AU","PSQ","TQQQ","MNQmain","NVIW.SI",".IXIC","TSYW.SI","SQQQ","USJW.SI","NQmain","RBA","OS","BK4137","LU1303367103.USD","LU0757428866.USD","BK4097","QID","USAW.SI","BK4139","IMMP","QLD"],"gpt_icon":1},{"id":"2510385742","title":"IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2510385742","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510385742?lang=en_us&edition=fundamental","pubTime":"2025-02-11 21:00","pubTimestamp":1739278800,"startTime":"0","endTime":"0","summary":"100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024098/0/en/IN8bio-Reports-Updated-Positive-Results-from-Phase-1-Trial-of-INB-100-in-Leukemia-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","HSCT","BK4539","INB","PFS","BK4139","CR","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU2065731478.USD","BK4097","BK4195","BK4006","BK4211","CRS","IE0031619046.USD","INAB","RIC","OS","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2510938383","title":"Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery","url":"https://stock-news.laohu8.com/highlight/detail?id=2510938383","media":"CNW Group","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510938383?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:00","pubTimestamp":1739275200,"startTime":"0","endTime":"0","summary":"Approval is based on the Phase 3 KEYNOTE-671 Trial. \"While we have made significant advancements for patients with advanced lung cancer, it remains the leading cause of cancer-related deaths in Canada. This underscores the importance of addressing lung cancer cases in earlier stages, to help improve patient outcomes,\" stated Dr. JonathanSpicer, thoracic surgeon and scientist at the McGill University Health Centre , Scientist in the Cancer Research Program at The Institute, Professor of Surgery at McGill University, and Medical Director of the McGill Thoracic Oncology Network. \"This recent approval adds another therapeutic option for patients with operable non-small cell lung cancer.\". \"Today, we've made a significant step forward with the approval of the first anti-PD-1 therapy in Canada for the perioperative treatment of resectable non-small cell lung cancer. This approval highlights our commitment to expanding treatment options for lung cancer patients,\" expressed André Galarneau, Ph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/health-canada-approves-mercks-keytruda-120000682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211331839.USD","LU0985320562.USD","IE00BLSP4239.USD","LU1917777945.USD","LU2361045086.USD","LU0965509010.AUD","LU1989772840.SGD","LU0006306889.USD","LU1066051498.USD","LU1037948541.HKD","LU2106854487.HKD","IE00BJT1NW94.SGD","SG9999001176.USD","LU2461242641.AUD","SG9999014567.USD","LU0070302665.USD","LU1116320737.USD","IE00BJJMRZ35.SGD","IE00BBT3K403.USD","BK4550","LU1989772923.USD","SG9999002224.SGD","LU1093756325.SGD","IE0009355771.USD","LU1066051225.USD","LU1093756168.USD","IE00B4R5TH58.HKD","LU0265550359.USD","LU0861579265.USD","SG9999013999.USD","SSI","LU0320765489.SGD","MRK","BK4588","LU1934455863.HKD","LU2023250843.SGD","LU0965509283.SGD","LU1699723380.USD","LU1989771016.USD","OS","LU2089984988.USD","BK4007","LU0058720904.USD","SG9999014575.USD","LU1037948897.HKD","IE000M9KFDE8.USD","LU1983299246.USD","SG9999014559.SGD","SG9999015341.SGD","SG9999002232.USD"],"gpt_icon":1},{"id":"2510815573","title":"Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510815573","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510815573?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:00","pubTimestamp":1739224800,"startTime":"0","endTime":"0","summary":"Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC. At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety signals identified. NEW YORK & TOKYO, February 10, 2025----Pfizer Inc.  and Astellas Pharma Inc.  today announced additional follow-up results from the Phase 3 EV-302 clinical trial  evaluating the efficacy and safety of PADCEV  , a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA , a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothelial cancer . The results showed a sustained overall survival  and progression-free survival  benefit consistent with the findings of the primary analysis after an additional 12 months of follow-up .1,2 These data will be p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b68b91779c1270fe944d25cf0021e5aa","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-astellas-padcev-enfortumab-vedotin-220000915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0289739699.SGD","BK4007","BK4080","BK4157","LU0861579265.USD","LU1037948897.HKD","LU1571399168.USD","LU1116320737.USD","ALPMF","LU1162221912.USD","LU1983299246.USD","AEIS","LU1585245621.USD","LU1934455277.USD","MRK","ALT","LU1093756168.USD","LU0208291251.USD","LU2089984988.USD","ADC","LU0122379950.USD","LU0234572021.USD","BK4585","LU0985481810.HKD","IE00B2B36J28.USD","LU1929549753.HKD","SG9999013999.USD","LU1883839398.USD","PFE","BK4534","IE0009355771.USD","LU0238689110.USD","BK4097","ALPMY","BK4516","OS","LU1057294990.SGD","PFS","LU0321505439.SGD","AST","TEN","LU1699723380.USD","IE0031619046.USD","BK4195","LU0320765646.SGD","IE00B66KJ199.SGD","BK4559","IE00BLSP4239.USD","LU0321505868.SGD","LU1023059063.AUD","LU1934455863.HKD"],"gpt_icon":1},{"id":"2510658854","title":"Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2510658854","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510658854?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:00","pubTimestamp":1739192400,"startTime":"0","endTime":"0","summary":"Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif., Feb. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/10/3023370/0/en/Tempest-Granted-Fast-Track-Designation-from-the-U-S-Food-and-Drug-Administration-for-Amezalpat-to-Treat-Patients-with-Hepatocellular-Carcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4225","IE00B5TLWC47.USD","ALD","BK4585","BK4006","BK4567","IE00BYQQ9H92.USD","OS","BK4588","BK4203","BK4183","HR","IE00BFXG0V08.USD","ODD","HCC","FAST","BK4104","BK4097"],"gpt_icon":0},{"id":"2510639918","title":"CVM: Fiscal Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2510639918","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510639918?lang=en_us&edition=fundamental","pubTime":"2025-02-10 17:15","pubTimestamp":1739178900,"startTime":"0","endTime":"0","summary":"CEL-SCI Corporation  reports fiscal year 2024 financial and operational results. The press release and Form 10-K filing encapsulate a year of preparation for confirmatory registration studies around the globe. CEL-SCI cleared its proposed 212-patient registration study of Multikine with the FDA. This narrowed the population to patients with squamous cell carcinoma of the head and neck  with no lymph node involvement and low PD-L1 tumor expression. A contract research organization  was selected to run the trial and data was presented from the IT-MATTERS study showing 73% survival for Multikine vs. 45% in the control arm at five years. Outside of the US, the European Medicines Agency  Pediatric Committee and the United Kingdom’s Healthcare Products Regulatory Agency  granted Multikine a pediatric waiver, streamlining the process for obtaining approval in these jurisdictions.CEL-SCI recognized no revenues for its fiscal year ending September 30, 2024. It consumed $26.4 million in operatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvm-fiscal-2024-results-091500108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4139","CVM","BK4097"],"gpt_icon":0},{"id":"2510026846","title":"Onestream, Inc. (OS) Among the Best Software Infrastructure Stocks to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2510026846","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510026846?lang=en_us&edition=fundamental","pubTime":"2025-02-10 02:27","pubTimestamp":1739125661,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Software Infrastructure Stocks to Buy According to Analysts. In this article, we are going to take a look at where Onestream, Inc.  stands against other best software infrastructure stocks to buy according to analysts.According to a January 2025 report by The Business Research Company, the infrastructure software market size is projected to grow from $210 billion in 2024 to $220 billion in 2025, with a growth rate of 5.1%. The market has experienced strong growth in recent years due to spending on legacy system modernization, the increase in remote work, cybersecurity concerns, automation, and application performance optimization. The research firm anticipates continued strong growth, with the market expected to reach around $283 billion by 2029, at a compounded annual growth rate  of 6.5%.To identify the 10 best software infrastructure stocks, we conducted extensive research to compile a list of fundamentally strong U.S. listed software infrastr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-inc-os-among-best-182741587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0225283273.USD","OS","LU1162221912.USD","USJW.SI","QID","IE00BKVL7J92.USD","LU1989772840.SGD","LU0912757837.SGD","QLD","LU2133065610.SGD","LU0267386448.USD","LU0314104364.USD","LU1668664300.SGD","BK4159","BK4581","CAGR","LU0158827781.USD","LU1732799900.SGD","LU2089284900.SGD","LU2271345857.HKD","LU0158827948.USD","PSQ","BK4534","LU0106261372.USD","LU1720051017.SGD","TQQQ","USAW.SI","LU0795875169.SGD","LU1720051108.HKD","NQmain","TSYW.SI","LU0006306889.USD","BK4127","LU2028103732.USD","SQQQ","LU1732800096.USD",".IXIC","MNQmain","LU1548497426.USD","LU1363072403.SGD","NVIW.SI","LU2357305700.SGD","LU0795875086.SGD","BK4097","LU0098860793.USD","LU0106831901.USD","LU2023251221.USD","LU1989772923.USD","BK4588"],"gpt_icon":1},{"id":"2509177113","title":"OneStream Inc  expected to post earnings of 2 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2509177113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509177113?lang=en_us&edition=fundamental","pubTime":"2025-02-08 05:27","pubTimestamp":1738963639,"startTime":"0","endTime":"0","summary":"OneStream Inc  expected to post earnings of2cents a share - Earnings Preview OneStream Inc OS.OQ OS.O is expected to report resultson February 11 for the period ending December 31 2024The Rochester Mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nL8N3OY2K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0},{"id":"2508454683","title":"MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2508454683","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508454683?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:51","pubTimestamp":1738677060,"startTime":"0","endTime":"0","summary":"Median overall survival  from THIO treatment extends to 16.9 months. CHICAGO, February 04, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, sequenced with Regeneron’s immune checkpoint inhibitor  cemiplimab  in patients with advanced non-small cell lung cancer  who failed two or more standard-of-care therapy regimens.THIO  is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer . Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine  induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-positive-efficacy-135100694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B66KJ199.SGD","CPI","LU0058720904.USD","LU1059921491.USD","IE00BSNM7G36.USD","ORR","LU0053666078.USD","LU0289739699.SGD","IE00B7SZL793.SGD","CI","OS","BK4196","BK4139","IE00B19Z3B42.SGD","BK4585","MAIA","L","LU1261432733.SGD","BK4213","BK4107","IE00B19Z4B17.USD","LU0868494617.USD","SOC","IE0031619046.USD","AEIS","IE00B19Z3581.USD","BK4157","IE0002270589.USD","BK4588","BK4097"],"gpt_icon":0},{"id":"2508430119","title":"KKR quarterly profit beats expectation on dealmaking revival","url":"https://stock-news.laohu8.com/highlight/detail?id=2508430119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508430119?lang=en_us&edition=fundamental","pubTime":"2025-02-04 19:52","pubTimestamp":1738669951,"startTime":"0","endTime":"0","summary":"KKR quarterly profit beats expectation on dealmaking revival Feb 4 (Reuters) - Alternative asset manager KKR & Co KKR.N reported a fourth-quarter profit that beat Wall Street expectations on Tuesday, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nL4N3OU1KV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE0004445239.USD","BK4135","BK4588","LU1201861249.SGD","IE00B3QW5Z07.USD","IE00BN8TJ469.HKD","BK4585","LU1668664300.SGD","LU1935042488.USD","LU1791807156.HKD","BX","IE00BLSP4239.USD","LU0980610538.SGD","LU1935042991.SGD","IE00BBT3K403.USD","LU0130102774.USD","IE00BLSP4452.SGD","LU1935042215.USD","LU1935043536.SGD","BK4097","LU0106831901.USD","KKR","LU1935043023.USD","OS","LU0648001328.SGD","LU0314104364.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2508345850","title":"Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2508345850","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508345850?lang=en_us&edition=fundamental","pubTime":"2025-02-04 19:45","pubTimestamp":1738669500,"startTime":"0","endTime":"0","summary":"Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth. Excluding Contributions from Paxlovid and Comirnaty, Revenues Grew 12% Operationally. Full-Year 2024 Reported Diluted EPS of $1.41 and Adjusted Diluted EPS of $3.11. Fourth-Quarter 2024 Revenues of $17.8 Billion, Reflecting 21% Year-over-Year Operational Growth. Fourth-Quarter 2024 Reported Diluted EPS of $0.07 and Adjusted Diluted EPS of $0.63. On Track to Deliver Overall Net Cost Savings of Approximately $4.5 Billion by End of 2025 from Ongoing Cost Realignment Program. Reaffirms All Components of Full-Year 2025 Financial Guidance, including Revenues in a Range of $61.0 to $64.0 Billion and Adjusted Diluted EPS in a Range of $2.80 to $3.00. NEW YORK, February 04, 2025----Pfizer Inc.  reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance provided on December 17, 2024.The fourth-quarter 2024 earnings presentation and accompanying prepared rema","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e75b2b7dcb07c669b5aa92e4e319edbe","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-strong-full-2024-114500880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE00B19Z3B42.SGD","LU0122379950.USD","MBC","PFS","BK4533","IE00BLSP4452.SGD","BK4195","LU0234572021.USD","SG9999001176.USD","LU0170899867.USD","LU1883839398.USD","BK4166","BK4548","BK4551","BNTX","BK4139","LU1066051498.USD","BCG","LU0306806265.USD","SG9999002232.USD","BK4135","BK4097","BK4211","BK4592","LU0225771236.USD","SGXZ57979304.SGD","IE00BLSP4239.USD","ORR","BK4599","BK4503","BK4581","BK4201","IE00BBT3K403.USD","LU0225284248.USD","SG9999001176.SGD","LU0058720904.USD","EC","LU1894683348.USD","OS","PFE","LU0306807586.USD","LU0321505868.SGD","SG9999002224.SGD","BK4535","QD","BK4568","LU0868494617.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2508124253","title":"Pfizer's Groundbreaking Cancer Drug Hits a Major Milestone--What It Means for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2508124253","media":"GuruFocus.com","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508124253?lang=en_us&edition=fundamental","pubTime":"2025-02-04 03:08","pubTimestamp":1738609712,"startTime":"0","endTime":"0","summary":"Pfizer  just dropped some big news, and it's a game-changer for cancer treatment. The company announced top-tier results from its Phase 3 BREAKWATER trial of BRAFTOVI  in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer  harboring a BRAF V600E mutation. The data is strongshowing a statistically significant and clinically meaningful improvement in progression-free survival  and overall survival . For a patient group that has long had limited treatment options, this is a massive step forward. No new safety signals were identified during the ORR analysis, with the safety profile of BRAFTOVI, in combination with cetuximab and mFOLFOX6, remaining consistent with what's known for each agent. Pfizer's not slowing down. The company is now working to get full approval for this breakthrough treatment, pushing forward to bring it to more patients worldwide. For investors, this could be just the start of bigger things ahead, as Pfizer strengthens its foothold ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizers-groundbreaking-cancer-drug-hits-190832680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1894683264.USD","BK4195","LU1894683348.USD","LU0306806265.USD","LU0170899867.USD","LU0456855351.SGD","BK4097","LU0225771236.USD","LU0306807586.USD","LU0289739699.SGD","LU0321505868.SGD","LU0321505439.SGD","LU1883839398.USD","BK4568","BK4592","LU1057294990.SGD","IE000M9KFDE8.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU0234572021.USD","BK4211","LU1023059063.AUD","SG9999003800.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU0985481810.HKD","BK4588","LU0058720904.USD","IE00BLSP4452.SGD","BK4007","BK4599","BK4533","PFE","LU0868494617.USD","SG9999002224.SGD","LU0225284248.USD","OS","IE00B19Z3B42.SGD","SG9999002232.USD","BK4581","PFS","SG9999013999.USD","BK4550","SG9999001176.USD","BK4534","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1066053197.SGD","SG9999011175.SGD","ISBC"],"gpt_icon":1},{"id":"2508492967","title":"Why Netflix's Excellent Performance Is a Great Reason to Buy Roku Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2508492967","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508492967?lang=en_us&edition=fundamental","pubTime":"2025-02-01 18:50","pubTimestamp":1738407000,"startTime":"0","endTime":"0","summary":"Strong streaming engagement is great for the industry, and Roku is on top.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/01/why-netflixs-excellent-performance-is-a-great-reas/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0079474960.USD","LU2357305700.SGD","BK4524","LU0006306889.USD","LU0417517546.SGD","LU0868494708.USD","LU0097036916.USD","IE00BQXX3D17.EUR","LU1035775433.USD","LU1429558221.USD","LU1823568750.SGD","BK4108","IE00BQXX3C00.GBP","SG9999004303.SGD","ROKU","BK4507","LU1720051017.SGD","LU2362540622.SGD","LU2362541513.USD","LU0256863902.USD","LU0106261372.USD","LU2362541273.HKD","LU2237957902.USD","LU1861559042.SGD","IE00B19Z8X17.USD","LU1069344957.HKD","LU2326559502.SGD","NFLX","BK4548","LU1064131342.USD","LU0786609619.USD","IE00BKPKM429.USD","LU0868494617.USD","LU1814569148.SGD","LU1861558580.USD","BK4527","OS","BK4532","LU2237957811.SGD","LU1046421795.USD","LU1720051108.HKD","BK4534","LU0942090050.USD","SGXZ51526630.SGD","LU2264538146.SGD","LU0225283273.USD","BK4585","IE00BQXX3F31.USD","SGXZ99366536.SGD","LU1435385759.SGD"],"gpt_icon":1},{"id":"2507957164","title":"Immutep Quarterly Activities Report Q2 FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2507957164","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507957164?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer  received first regulatory approval. Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival  and 81.0% 24-month OS rate, significantly outperforming historical controls. Promising new results in first line head & neck cancer with PD-L1 CPS <1 reported at ESMO IO 2024, with median OS not reached and 67% 12-month OS rate well above historical controls. Phase II in soft tissue sarcoma shows three-fold increase in tumour hyalinization  compared to historical data from radiotherapy. Phase I trial of IMP761 reported favourable initial safety results advancing the first-in-class agonist LAG-3 antibody program. TACTI-004 – Start of Phase III Trial in 1L NSCLCIn December 2024, Immutep initiated its pivotal TACTI-004 Phase III clinical trial of eftilagimod alfa  for the treatment of first-line metastatic non-small cell ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-quarterly-activities-report-q2-130000670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","INAQU","BK4097","BK4211","BK4104","IMMP","IO","CTOS","PFS","BK4179","BK4139","IMM.AU","BK4563","ORR","BK4195"],"gpt_icon":0},{"id":"2507659161","title":"Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2507659161","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507659161?lang=en_us&edition=fundamental","pubTime":"2025-01-30 01:37","pubTimestamp":1738172220,"startTime":"0","endTime":"0","summary":"These findings further reinforce the consistency of the BOT/BAL combination, which has already shown activity and a favorable safety profile across both multiple \"warm and cold\" tumor types, including colon cancer, lung cancer, melanoma and ovarian cancers.Patients with advanced sarcomas face poor outcomes and have limited treatment options, underscoring the urgent need for innovative therapies. This Phase 1 study evaluated the safety and efficacy of botensilimab , an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab , an anti-PD-1 antibody, in this challenging patient population.\"The publication in the Journal of Clinical Oncology further underscores the significant potential of botensilimab and balstilimab to address ‘cold’ tumors like certain subtypes of refractory sarcomas,\" said Dr. Breelyn A. Wilky, University of Colorado Cancer Center. \"These findings highlight the ability of this combination to deliver meaningful clinical benefits, including durable responses an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agenus-announces-publication-journal-clinical-173700119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","L","BK4588","OS","BK4097","TRAE","PFS","BAL","BK4195","BK4211","BK4585","BK4107","LU0053666078.USD","AGEN","ORR"],"gpt_icon":0},{"id":"2507472975","title":"IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25…","url":"https://stock-news.laohu8.com/highlight/detail?id=2507472975","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507472975?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:10","pubTimestamp":1738073400,"startTime":"0","endTime":"0","summary":"Imunon, Inc.  is continuing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin -12 expressing plasmid that allows for the durable, local, and targeted expression of IL-12 in the peritoneum. IL-12 is a potent pro-inflammatory cytokine that mediates a number of important cellular processes, including T cell and natural killer cell activation , the production of interferon-gamma , and alteration of myeloid-derived suppressor cells in the tumor microenvironment . While shown to be effective in pre-clinical tumor models, IL-12 therapy initially showed underwhelming results in the clinic along with very high levels of toxicity when administered systemically. This is likely due to the fact that the direct targets of IL-12 are not circulating lymphocytes, but rather immune cells located within the tumor and lymph nodes. Thus, while systemi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imnn-gearing-initiate-phase-3-141000805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0267386448.USD","LU0882574139.USD","IE00BHPRN162.USD","LU0170899867.USD","BK4097","BK4113","CMC","LU0149725797.USD","BK4006","LU0053671581.USD","HR","BK4139","IE00BKVL7J92.USD","ITT","IE00B1BXHZ80.USD","BK4225","LU0971096721.USD","BK4203","LU1363072403.SGD","OS","IE00BZ1G4Q59.USD","LU0054578231.USD","BK4161","IMNN","CBD"],"gpt_icon":0},{"id":"2506539108","title":"ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2506539108","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506539108?lang=en_us&edition=fundamental","pubTime":"2025-01-28 07:00","pubTimestamp":1738018800,"startTime":"0","endTime":"0","summary":"Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year. Approval brings AstraZeneca and Daiichi Sankyo’s ENHERTU to an earlier HR-positive treatment setting and broadens the patient population eligible for treatment with a HER2-directed therapy to those with HER2-ultralow disease. WILMINGTON, Del., January 27, 2025----AstraZeneca and Daiichi Sankyo’s ENHERTU  has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor -positive, HER2-low  or HER2-ultralow  breast cancer, as determined by a Food and Drug Administration -approved test, that has progressed on one or more endocrine therapies in the metastatic setting.The approval was granted by the FDA after securing Priority Review and Breakthrough Therapy Designation and was based on results from the DESTINY-Breast06 Phase III trial, which were presented at the 2024 A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-fam-trastuzumab-deruxtecan-nxki-230000535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4007","BK4211","AZN","LU0109394709.USD","BK4225","LU0889565916.HKD","LU2462157665.USD","BK4588","BK4203","HR","LU2236285917.USD","LU1829250122.USD","LU2417539215.USD","BK4585","ADC","LU0320765992.SGD","BK4195","LU2456880835.USD","OS","PFS","BK4080","ORR","BK4231","BK4097"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"date":"2025-05-08","symbol":"OS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.06,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3158,"buy":0.5789,"hold":0.1053,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5789,"analysts":19,"updateTime":1742356800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-04-29","current":-17.178873,"percent":0.901639,"low":-1655.61542,"twenty":-1413.843009,"median":-27.388849,"eighty":-18.7477,"high":-14.493656,"avg":-426.817199,"sd":615.425447,"marketCap":3714089583},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-04-29","current":-17.178873,"twenty":-1413.843009,"median":-27.388849,"eighty":-18.7477,"marketCap":3714089583}],"updateTime":1746085438295}}}